IP Library Granted Patent US 9,457,070
Granted Patent B2
US 9,457,070 · App. 13/209,349 · Granted Oct 4, 2016

Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease

Inventors: Charles A. Dinarello (Boulder, CO); Eli C. Lewis (Be'er Sheva, IL)
Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
A61K38/57C12Q1/37A61K31/60A61K38/12A61K38/179G01N2333/81G01N2333/96433G01N2800/245
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,070
App. No.
13/209,349
Granted
Oct 4, 2016
Kind
B2
Abstract

Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.

Claims (5)

1. A method for treating acute graft versus host disease (GvHD) in a human subject in need thereof, said method comprising administering to the human subject a composition comprising alpha 1-antitrypsin (AAT) and treating GvHD in the human subject.

2. The method of claim 1 , wherein the composition further comprises one or more anti-inflammatory agents.

3. The method of claim 1 , wherein the AAT is full-length and is part of a fusion polypeptide.

4. The method of claim 3 , wherein the fusion polypeptide comprises the full-length AAT fused to an immunoglobulin constant region.

5. The method of claim 1 , wherein the human subject has undergone allogeneic bone marrow implantation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2026
From: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
To: IMMUNASE BIO, LLC
Reel/Frame 075547/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2012
From: DINARELLO, CHARLES A.; LEWIS, ELI C.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 029132/0203 →
Continuity (3)
Continuation In Part 11916521
Provisional Application 60687850 · Jun 7, 2005
Related Publication 20120045449A1 · Feb 23, 2012